DARE.US Dare Bioscience Inc

Healthcare Health Care Equipment & Supplies USA Stocks
0.6574 USD
Close of Nov 14, 2026
0.6100 3.78
Market cap
USD 12.9M
P/E
-
P/B
29.40x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is DARE.US undervalued?

Graham number

The Graham number of Dare Bioscience Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dare Bioscience Inc fundamental analysis

No fundamental analysis for Dare Bioscience Inc yet.

Dare Bioscience Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dare Bioscience Inc

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment…

Full company profile